Neurocrine biosciences presents new three-year data demonstrating sustained clinical benefits and established safety profile of ingrezza® (valbenazine) capsules for huntington's disease chorea

Once-daily ingrezza treatment was generally well tolerated and showed early and sustained improvements in chorea severity findings presented at 2025 mds international congress of parkinson's disease and movement disorders®  san diego , oct. 6, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today presented new data from the open-label kinect®-hd2 study demonstrating an established long-term safety profile, tolerability and sustained improvements in chorea severity through three years of treatment with once-daily ingrezza® (valbenazine) capsules in adults with huntington's disease. these findings were presented at the 2025 mds international congress of parkinson's disease and movement disorders in honolulu.
NBIX Ratings Summary
NBIX Quant Ranking